Research programme: drug discovery - Advinus Therapeutics/Takeda
Latest Information Update: 28 Jul 2018
At a glance
- Originator Advinus Therapeutics; Takeda
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Inflammation; Metabolic disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in CNS-disorders in India
- 28 Jul 2018 No recent reports of development identified for research development in CNS-disorders in Japan
- 28 Jul 2018 No recent reports of development identified for research development in Inflammation in India